Prima holds collaborations with several partners.
LAG-3 Technology related collaborations
- IMP321 development is being manufactured in conjuntion with Eddingpharm who have licensed rights for China including Macau, Hong Kong and Taiwan. Prima owns the rights to the rest of the world.
- A Phase I program with a LAG-3 depleting antibody in autoimmune diseases is partnered with GlaxoSmithKline;
- A Phase I program in immune checkpoint blockade by LAG-3 for cancer immunotherapy is partnered with Novartis.
- A tripartite manufacturing contract for IMP321 is in place between Eddingpharm and WuXi AppTec (China).